Opella Shifts Enterogermina Production to Mexico

Opella has transferred production of its flagship probiotic Enterogermina from Italy to Mexico, marking a major milestone in the company's manufacturing strategy for the Americas. The move is supported by a US$70 million investment in a new production line at its Ocoyoacac facility in the State of Mexico, part of a broader US$135 million expansion plan running through 2028.

The expansion transforms the Ocoyoacac plant into the company's second global manufacturing hub for Enterogermina, complementing its long-established facility in Origgio, Italy. For the first time, the Mexican site will produce both the active pharmaceutical ingredient and the finished product, bringing advanced manufacturing capabilities that were previously concentrated in Europe.

The new production line adds an annual capacity of 200 million mini-bottles, enabling Opella to meet growing demand across Latin America while strengthening the resilience of its global supply network. Company executives said producing closer to key markets will improve supply chain efficiency and support faster regional distribution.

As production ramps up, the share of Opella products sold in Mexico that are manufactured locally will increase from 60% to 80%. The company also expects the facility to play a larger role as an export platform, supplying multiple Latin American markets from Mexico.

Beyond expanding manufacturing capacity, the investment includes a significant transfer of industrial expertise and production technology. According to the company, the project equips the Mexican operation with specialized know-how and quality systems required to manufacture one of the world's leading probiotic brands under the same standards applied in Europe.

The Ocoyoacac facility also supports Opella's sustainability objectives. The site operates with 100% renewable electricity, has significantly reduced carbon emissions over the past several years, and follows a zero-waste-to-landfill model, aligning manufacturing expansion with the company's environmental commitments.

With the relocation of Enterogermina production, Mexico assumes a more strategic role within Opella's global manufacturing network, reinforcing the country's position as an emerging pharmaceutical production and export hub for the Americas.